InvestorsHub Logo
Followers 33
Posts 2837
Boards Moderated 2
Alias Born 10/24/2015

Re: growacet post# 971

Sunday, 05/22/2016 10:27:29 AM

Sunday, May 22, 2016 10:27:29 AM

Post# of 1228
I've just come across this http://global.onclive.com/web-exclusives/oncolytic-poliovirus-receives-breakthrough-designation-for-glioblastoma ''For the 24 patients analyzed for the ASCO poster, the median age was 57.5 years (range 20-70). The KPS was most commonly 90% (62.5% of patients). Prior therapies included radiation (100%), temozolomide (100%), and bevacizumab (41.7%).

At a data cutoff of May 19, 2015, the median OS across all doses of PVS-RIPO was 12.5 months (95% CI, 6.3-19.8). The 12-month OS rate was 56% (95% CI, 28.7-56.3%) and the 18-month rate was 32% (95% CI, 10.4-56.3%). At this analysis, 11 patients had failed treatment with PVS-RIPO.''

Sadly the media has been distorting the results with saying things like ''Results in the earliest stage of testing have been so remarkable, the FDA wants to fast track the treatment to speed it to market'' and ''Could POLIO help cure cancer? Therapy harnessing the virus 'destroys brain tumors.'' After reading the data I'm somewhat encouraged but it's still early days.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TCRT News